Regentis Biomaterials Ltd (RGNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 06-2025 | 12-2024 | 12-2023 | 12-2001 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,378 | 189 | 229 | 345 | N/A |
| Other current assets | 240 | 286 | 253 | 15 | 680 |
| TOTAL | $7,618 | $475 | $482 | $360 | $680 |
| Non-Current Assets | |||||
| Investments And Advances | 0 | 0 | 0 | 0 | 490 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 2,570 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $3,060 |
| Total Assets | $7,618 | $475 | $482 | $360 | $3,740 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,197 | 8,164 | 4,945 | 210 | 13,150 |
| Accounts payable and accrued liabilities | 266 | 1,545 | 252 | 353 | 5,100 |
| Accrued Expenses | 0 | N/A | 0 | 0 | 1,190 |
| Other current liabilities | 1,411 | N/A | 1,291 | 2,576 | 0 |
| TOTAL | $2,874 | $9,709 | $6,488 | $3,139 | $21,910 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 35,098 | 35,098 | 43,126 | 2,550 |
| TOTAL | $N/A | $35,098 | $35,098 | $43,126 | $13,100 |
| Total Liabilities | $2,874 | $44,807 | $41,586 | $46,265 | $35,010 |
| Shareholders' Equity | |||||
| Common Shares | 0 | N/A | 0 | 0 | 10,610 |
| Retained earnings | -55,794 | -45,374 | -42,146 | -46,947 | N/A |
| TOTAL | $4,744 | $-44,332 | $-41,104 | $-45,905 | $10,610 |
| Total Liabilities And Equity | $7,618 | $475 | $482 | $360 | $45,620 |